Many start-ups are developing diabetes drugs based on known targets which could attract Big Pharma partners and get to the clinic quickly, while a few invest in novel compounds that are either riskier or address the field's smaller subsets. Among the former are Phenomix, Plexxikon, CareX and Prosidion; among the latter are DiaKine, and DiaMedica. In all cases, these companies are looking to partner with Big Pharma, which is aggressively pursuing small-molecule drugs for diabetes.
By Wendy Diller
Big news in the diabetes field. In the next two months, the FDA is slated to decide whether to approve...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
The Belgian drugmaker is boosting its biologics capacity over the pond.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.
